Tocilizumab (TCZ), a humanized monoclonal antibody targeting the IL-6 receptor subunit alpha (IL-6Ra), has demonstrated a significant efficacy against rheumatoid arthritis. Here, IL6R is linked to rheumatoid arthritis.